Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26. Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr.
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
Shanghai Medicilon Inc.
Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China